



(51) International Patent Classification:

A61K 9/00 (2006.01) C12N 5/0793 (2010.01)
A61K 38/48 (2006.01) C12N 7/01 (2006.01)
A61K 48/00 (2006.01) C12N 9/48 (2006.01)
A61P 25/00 (2006.01) C12N 15/864 (2006.01)

(21) International Application Number:

PCT/US2024/013505

(22) International Filing Date:

30 January 2024 (30.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/482,495 31 January 2023 (31.01.2023) US

(71) Applicant: **THE CHILDREN'S HOSPITAL OF PHILADELPHIA** [US/US]; 3401 Civic Center Boulevard, Philadelphia, Pennsylvania 19146 (US).

(72) Inventors: **DAVIDSON, Beverly**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **RANUM, Paul**; c/o The Children's Hospital of Philadelphia, 2716 South

Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **CHEN, Yonghong**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **KEISER, Megan S.**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US). **TECEDOR, Luis**; c/o The Children's Hospital of Philadelphia, 2716 South Street, 15th Floor, Philadelphia, Pennsylvania 19146 (US).

(74) Agent: **HIGHLANDER, Steven L.**; Parker Highlander PLLC, 1120 S. Capital of Texas Hwy, Building One, Suite 200, Austin, Texas 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: NOVEL GENE THERAPY CONSTRUCT FOR CLN2 DISEASE




FIG. 6

(57) Abstract: Provided herein are methods of expressing a tripeptidyl peptidase 1 (TPP1) in a neuron. Also provided herein is a modified adeno-associated virus (AAV) encoding a TPP1 under the control of a promoter operable in a neuron or ependyma cell, and not in dorsal root ganglia.

